Loading...
Loading...
WINT| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 4,741.0K |
| Operating I/L | -4,741.0K |
| Other Income/Expense | 1,752.0K |
| Interest Income | 12.0K |
| Pretax | -2,989.0K |
| Income Tax Expense | -240.0K |
| Net Income/Loss | -2,749.0K |
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutics for acute cardiovascular and pulmonary diseases. The company's lead programs include istaroxime for acute decompensated heart failure and early cardiogenic shock, AEROSURF for respiratory distress syndrome in premature infants, Lyophilized KL4 surfactant for lung injury from COVID-19, and Rostafuroxin for genetically associated hypertension. Windtree has collaborations for SERCA2a compounds with Universita degli Studi di Milano-Bicocca, KL4 surfactant products with Laboratorios del Dr. Esteve, S.A., and ADS development with Battelle Memorial Institute.
